insights_auto
Kwa nini GIS imeongezeka kwa 3.58%?
Fahamu zaidichevron_right
GIS:FRA
Gilead Sciences, Inc
€ 135.56
arrow_upward
+3.58%(+4.68) Siku 1
12 Okt, 15:56:42 GMT +2 · EUR
search
Alama zote
| Alama | Bei | Tofauti | Tofauti ya asilimia |
|---|
insights_autoInatayarisha maarifa maarufu ya GIS...
Fungua
€ 134.80
Juu
€ 135.56
Chini
€ 134.80
Mtaji wa soko
186.33B
Wastani wa kiasi cha mauzo
386.00
Kiasi cha mauzo ya hisa
elfu 1.16
Juu kwa wiki 52
€ 135.56
Chini kwa wiki 52
€ 97.79
Idadi ya wafanyakazi
elfu 17
Fungua
€ 134.80
Juu
€ 135.56
Chini
€ 134.80
Mtaji wa soko
186.33B
Wastani wa kiasi cha mauzo
386.00
Kiasi cha mauzo ya hisa
elfu 1.16
Juu kwa wiki 52
€ 135.56
Chini kwa wiki 52
€ 97.79
Idadi ya wafanyakazi
elfu 17
Habari
Kutoka kwenye vyanzo vya wavuti na washirika wa habari
Yahoo Finance
·
saa 3 zilizopita
Gilead Sciences' Yeztugo Survey Supports Long-Term Growth Outlook, BofA Says
ad-hoc-news.de
·
saa 4 zilizopita
Gilead Sciences stock trades at EUR 135.59, volume 17.2 percent above average
Insider Monkey
·
saa 4 zilizopita
Can Gilead (GILD) Stock Continue Rising in 2027?
Investing.com
·
saa 6 zilizopita
BofA raises Gilead Sciences stock price target on growth outlook
Wasifu
Gilead Sciences, Inc. is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV/AIDS, hepatitis B, hepatitis C, influenza, and COVID-19. It also develops medicines in therapeutic areas such as oncology and inflammation and cell therapy.
In 1987, Michael L. Riordan founded the company under the name Oligogen. The original name was a reference to oligonucleotides, small strands of DNA used to target genetic sequences. Gilead held its initial public offering in 1992, and successfully developed drugs including Tamiflu and Vistide that decade.
In the 2000s, Gilead began evolving from a biotechnology company into a large pharmaceutical company, through acquisitions and investments, acquiring several subsidiaries. Gilead is a member of the Nasdaq-100 and the S&P 100.
The company has faced criticism over its business practices, including extremely high pricing of drugs such as Sovaldi and Truvada in the United States relative to production cost and cost in the developing world. Wikipedia
Kuhusu Gilead Sciences, Inc
Afisa Mkuu Mtendaji (CEO)Daniel O'Day
Wafanyakazielfu 17
Lilianzishwa22 Jun 1987
Makao makuuFoster City, California, Marekani
Sekta-
Tovutigilead.com